Trials and Fibrillations with Dr John Mandrola

 
 

Trials and Fibrillations with Dr John Mandrola

  • TCT 2022 Neutral Trial, Positive Spin: PROTECTED TAVR The primary endpoint was negative for a trial of embolic protection during transcatheter aortic valve replacement, yet the paper's conclusion emphasized the potential benefit.
  • ESC 2022 Judicious CVD Screening May Work in Men: DANCAVAS Comprehensive cardiac screening in men over 65 years seemed to be of benefit but the Danish setting may be key, writes John Mandrola, MD. Would U.S. screeners be as conservative with their interventions?
  • ESC 2022 PCI Fails in Stable Disease Again: REVIVED-BCIS Yet another null finding for stenting in stable patients leads this cardiologist to wonder whether the next generation of cardiologists will end the sclerotic clogged-pipe frame of treating atherosclerosis.
  • ESC 2022 Do SGLT2 Inhibitors DELIVER in All Heart Failure? The investigators of the DELIVER trial and others suggest that all patients with heart failure get SGLT2 inhibitors, but this cardiologist sees differing effects depending on ejection fraction.
  • ESC 2022 CAPLA Challenges Expert Opinion on Ablation of Persistent AF A trial presented at the European Society of Cardiology teaches that less is more in ablation for persistent AF and reminds clinicians to demand data before adopting aggressive procedures
  • ESC 2022 Mandrola Previews His Top 5 Trials From ESC 2022 Dr John Mandrola gives some insight on his choices for important trials to look for at this weekend's European Society of Cardiology Congress in Barcelona
  • Medical Necessity vs Therapeutic Fashion How will the sharp eye of history view the procedures and tests we routinely do? Could better critical appraisal sort the medically necessary from those that will eventually fall out of fashion?
  • Why I've Changed My Mind About Shared Decision-Making Shared decision-making is too often an excuse for dubious care, leading this cardiologist to have a change of heart.
  • HRS 2022 Taking Cardiac Pacing From Boring to Super-Cool Ablation has hogged the electrophysiology spotlight recently, but three presentations at the 2022 Heart Rhythm Society meeting put cardiac pacing on the comeback trail.
  • ACC 2022 Sodium Restriction in Heart Failure: Another Dogma Felled If you still think that strict sodium limits are worthwhile in patients with heart failure, the onus is on you to prove it. They have enough to deal with, writes John Mandrola, MD.
  • ACC 2022 Percutaneous Left Atrial Appendage Occlusion: Promise vs Reality The selling point of percutaneous left atrial appendage occlusion is to prevent stroke while avoiding the bleeding risk of antithrombotics. The data paint a different picture, writes John Mandrola, MD.
  • ACC 2022 Mavacamten in HCM: Reasons for Optimism and Caution The novel drug helped patients avoid septal reduction therapy in the short term and approval looks likely, but more details and longer-term safety data will be needed before broader use, writes John Mandrola, MD.
  • ACC 2022 Mandrola Previews ACC 2022 Studies on sodium restriction, fractional flow reserve, and strategies to improve patient and clinician behavior intrigue, but the best part of ACC22 is that it's largely in-person, writes John Mandrola, MD.
  • CardioMEMS Remote HF Monitoring: Resist the Spin and FOMO An expanded indication based on a dubious post hoc analysis of GUIDE-HF should not allow the CardioMEMS HF system to become the therapeutic fashion, writes John Mandrola, MD.
  • Mandrola's Top 10 Cardiology Stories of 2021 Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive -- these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.
  • AHA 2021 PCI vs CABG for Left Main CAD: A Never-Ending Debate? Controversies surrounding the EXCEL trial left questions about the data on stents vs bypass surgery in left main CAD. John Mandrola, MD, reviews a new independent meta-analysis presented at the 2021 AHA.
  • AHA 2021 Early Surgery in Asymptomatic AS Should Wait Another trial favoring early surgery in patients with asymptomatic aortic stenosis is still not enough to change practice, argues this cardiologist.
  • AHA 2021 Questions Remain on Tricuspid Repair at Time of Mitral Surgery The Cardiothoracic Surgical Trials Network trial on repair of mild-to-moderate tricuspid regurgitation in patients undergoing mitral valve surgery leaves this cardiologist with more questions than answers.
  • AHA 2021 Mandrola Previews the Virtual AHA 2021 Trials on aortic stenosis, atrial fibrillation, and a pragmatic use of EHRs are among the picks from this year's American Heart Association scientific sessions.
  • The MI–Mortality Mismatch: When Lowering MI Doesn't Extend Life An analysis challenges the notion that cardiovascular therapies that lower myocardial infarction extend survival. John Mandrola, MD, sees lessons for clinicians, patients, and researchers.